According to a study by Yun et al., mutations in KRAS and BRAF upregulated glucose transporter GLUT-1 and increased glucose uptake in CRC cells, while mitochondrial function and oxidative respiration were not impaired [139]. This evidence concerns the gene KRAS and colorectal carcinoma.